Avalyn Pharma Amends Charter & Bylaws for IPO; Authorizes 700M Shares

Avalyn Pharma Inc. filed an amended and restated certificate of incorporation and amended and restated bylaws in connection with the consummation of its initial public offering. The Restated Certificate authorizes 700 million shares of common stock, including 500 million voting and 200 million non-voting shares, and 10 million shares of undesignated preferred stock, while eliminating prior preferred stock series. The Amended and Restated Bylaws establish procedures for stockholder actions and nominations, conforming to the new certificate.